Friday, July 31, 2026

Kim Jong Un Personally Oversees Memorial Tied to North Korea’s Overseas Troops

Kim Jong Un inspects a memorial for soldiers in the Ukraine conflict, emphasizing their heroism and the project's significance.

Revolutionizing Healthcare: How Low-Risk NK Cell Therapy is Changing Regenerative Medicine in 2026

The Ministry of Health reclassifies autologous immune cell cultivation as low risk, expediting treatment access while ensuring safety.

How International Collaboration is Revolutionizing Infectious Disease Research in Asia

Korea's Disease Control Agency establishes a framework for local medical institutions to join international clinical trials for infectious diseases.

Tag: ABL Bio

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

ABL Bio to Launch Global Phase 3 Trial of ABL111 in December, Targeting First-Line Gastric Cancer Treatment

ABL Bio will begin global Phase 3 trials for its dual antibody gastric cancer treatment 'ABL111' this December after FDA discussions.

ABL Bio to Launch Global Phase 3 Trial of Gastric Cancer Drug Givastomig This Year at BIO USA

ABL Bio plans a Phase 3 trial for gastric cancer therapy Givastomig, targeting a $2.5 billion market opportunity.

ABL Bio to Showcase Dual-Target ADC Candidate ABL209 at World ADC Korea 2026

ABL Bio will showcase its dual-target ADC candidate ABL209 at the World ADC Korea 2026, focusing on enhanced cancer treatment.

ABL209: The Promising Dual Antibody ADC Revolutionizing Cancer Treatment in 2026

ABL Bio's ABL209 shows promising anti-cancer effects with broad safety in preclinical studies, advancing to Phase 1 trials in the U.S.

FDA Grants Orphan Drug Status to Tovecimig: What This Means for Cholangiocarcinoma Treatment

ABL Bio's Tovecimig receives Orphan Drug Designation from the FDA, enhancing its approval prospects for cholangiocarcinoma treatment.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

Unlocking Cancer Treatment: ABL206 and ABL209’s Promising Non-Clinical Data Revealed at AACR

ABL Bio will present preclinical data for its ADCs ABL206 and ABL209 at AACR 2023, showcasing promising anti-cancer efficacy.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

How ABL Bio’s Grabody-B Revolutionizes siRNA Delivery: A Game-Changer for Brain Disease Treatment?

ABL Bio's Grabody-B technology effectively delivers siRNA across the blood-brain barrier, enhancing treatment for brain and systemic diseases.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.